Abstract

ICU Medical will report second-quarter 2026 results on August 6, 2026, Post Market, with consensus pointing to broadly steady revenue near the prior quarter and higher adjusted EPS as investors watch mix, margins, and any regulatory developments tied to IV set components.

Market Forecast

Consensus for the current quarter centers on revenue of 533.43 million US dollars, a year-over-year change of -1.67%, adjusted EPS of 1.91 with a year-over-year increase of 27.57%, and EBIT of 83.83 million US dollars with a year-over-year increase of 17.08%. Gross margin and net margin have not been explicitly guided for the quarter in the available forecasts, though recent performance provides a reference point for investors.

Within the company’s core revenue mix last quarter, Infusion Consumables contributed 278.28 million US dollars (52.48% of sales), Infusion Systems 179.60 million US dollars (33.87%), and Critical Care 72.35 million US dollars (13.64%). The primary growth potential near term is concentrated in Infusion Consumables given its scale and recurring demand, anchored by 278.28 million US dollars of last quarter revenue; year-over-year segment growth was not disclosed.

Last Quarter Review

In the prior quarter, ICU Medical delivered revenue of 525.77 million US dollars (down 12.30% year over year), a gross margin of 38.89%, GAAP net profit attributable to shareholders of 30.13 million US dollars with a net margin of 5.68%, and adjusted EPS of 1.97 (up 14.54% year over year). A key financial highlight was operating discipline: EBIT reached 83.42 million US dollars, growing 2.86% year over year, while adjusted EPS exceeded the prior consensus by approximately 0.22. Main business composition was stable, led by Infusion Consumables at 278.28 million US dollars, followed by Infusion Systems at 179.60 million US dollars and Critical Care at 72.35 million US dollars; segment-level year-over-year deltas were not disclosed.

Quarter-on-quarter momentum in profitability improved materially, with net profit growing by 291.51% sequentially, reflecting stronger mix, cost control, and operating leverage flowing through to the bottom line even as the top line declined year over year. Taken together, the quarter featured revenue pressure but clear progress on margins and earnings delivery.

Current Quarter Outlook

Main business: revenue cadence, margin guardrails, and mix

The quarter is expected to show a relatively flat revenue profile on a sequential basis, with consensus placing sales at 533.43 million US dollars and year-over-year change at -1.67%. The revenue mix has been anchored by Infusion Consumables and Infusion Systems, which together accounted for 86.35% of last quarter sales. This concentration means small shifts in volume, pricing, or product mix in these lines can exert a noticeable impact on both the top line and gross margin.

A principal swing factor for margin is product mix within infusion. Disposables and high-throughput consumable lines typically support steadier gross margin characteristics relative to capital or set-based systems that can be more sensitive to input costs and pricing dynamics. The most recent quarter’s 38.89% gross margin, alongside a 5.68% net margin, establishes a reference point for investors monitoring whether the company can hold or expand profitability should revenue remain roughly stable. Overhead absorption, inventory turns, and freight and materials normalization continue to matter for gross margin trajectory; even modest operational improvements can extend to EBIT, which is projected at 83.83 million US dollars this quarter, implying year-over-year growth of 17.08% despite the anticipated revenue decline.

Adjusted EPS is projected at 1.91, up 27.57% year over year, suggesting consensus expects margin and cost leverage to offset the slight top-line pressure. This view aligns with the previous quarter’s pattern, when adjusted EPS increased year over year even as revenue fell. Investors will likely watch whether operating expenses track in line with revenue and whether prior cost initiatives continue to show through; the run-rate from last quarter’s performance provides reasonable context for assessing whether this quarter’s EPS can meet the implied improvement.

Most promising business: Infusion Consumables as earnings anchor

Infusion Consumables generated 278.28 million US dollars last quarter, representing 52.48% of revenue, and remains the largest earnings anchor in the portfolio. This scale provides a buffer for quarterly variability in other lines and supports margin stability when volume is balanced against procurement and manufacturing cost control. Given the recurring and embedded nature of these products in customer usage patterns, revenue in this area tends to connect to installed procedure volumes and purchasing cycles, which can smooth out volatility versus more episodic system orders.

While explicit year-over-year growth for Infusion Consumables was not disclosed, the substantial revenue contribution implies that even modest unit growth, pricing, or product mix improvements can translate into meaningful gross profit dollar support. In this context, consensus modeling for higher adjusted EPS year over year despite a slight revenue decline suggests that product cost management and favorable mix within consumables could underpin earnings quality this quarter. Moreover, the margin construct from last quarter serves as a benchmark; if consumables volumes avoid downticks and costs remain contained, gross margin resilience near recent levels would be a plausible outcome.

Near-term attention will be on procurement costs, any lingering logistics or materials issues, and the cadence of reorders from key accounts. If these elements hold steady, Infusion Consumables can continue to be the ballast that sustains quarterly cash generation and operating margin, aligning with the projected EBIT advance. The degree of continuity in consumables demand, relative to systems-driven variability, is likely to feature prominently in how the quarter’s profitability shapes up.

Key stock-price drivers this quarter: gross margin trajectory, regulatory headlines, and earnings quality

Gross margin trajectory is a central determinant of equity reaction given stability in revenue expectations. With last quarter at 38.89%, even a small expansion can drive outperformance given operating leverage. Investors will parse commentary around input costs, mix within infusion, and any normalization tailwinds, recognizing that the consensus EPS uplift implicitly counts on margin efficiency. Sustained net margin near or above the recent 5.68% marker would corroborate the EBIT growth embedded in forecasts.

Regulatory headlines around specific IV line set components remain a watch item. Public communications indicated an ongoing evaluation of the scope of potentially affected IV tube sets and a recommendation to remove certain SKUs from use or sale. Any incremental update—scope narrowing or broadening—could modulate expectations for Infusion Systems volumes, near-term remediation expenses, or inventory adjustments. If the scope is contained, investors may view any direct revenue or cost impact as limited and nonstructural; commentary that clarifies extent, remediation timing, and customer communication could reduce uncertainty.

Earnings quality and cash conversion will influence sentiment alongside headline EPS. Given consensus expects adjusted EPS growth while revenue is down year over year, investors will differentiate between operating drivers (gross profit improvements and opex efficiency) versus non-operating tailwinds. Clarity on working capital, inventories tied to sets and systems, and capex or one-off charges will factor into how sustainable the earnings cadence appears. A reiteration or refinement of full-year directionality for revenue and margins, even if not numerically guided, would help anchor expectations post-print.

Infusion Systems: volume sensitivity and potential near-term variability

Infusion Systems contributed 179.60 million US dollars last quarter, or 33.87% of revenue, making it the second-largest line and a notable swing factor for quarterly variability. Systems revenue can be more sensitive to customer purchasing cycles, capital allocation timing, and any product-specific advisories, which can shift order timing from one quarter to another. Against a backdrop of consensus modeling only modest revenue change overall, the mix within systems—especially if order phasing or shipment timing deviates—can inform both top line and margin outcomes.

Potential regulatory or quality-related communications on specific IV line sets can influence sentiment around systems in the short term. The public acknowledgment of evaluating impacted models and recommending removal of certain sets introduces the possibility of incremental costs or revenue deferrals, though the magnitude ultimately depends on the scope. Investors will focus on whether any actions are tightly scoped, how quickly substitutes are deployed, and whether changes are transient. If management indicates limited scope and controlled remediation, the market may view the episode as manageable and non-run-rate.

From a margin perspective, systems profitability can widen or compress depending on mix, pricing, and absorption. Should volumes remain stable and remediation costs limited, systems can support gross profit dollars without materially pressuring margins. Conversely, if shipments are postponed or mix skews less favorably, leverage could soften. Management color on order pipeline health, backlog, and customer readiness to take deliveries in the second half will be important for how investors model the out quarters.

Critical Care: smaller revenue share with potential for steady contribution

Critical Care accounted for 72.35 million US dollars last quarter, or 13.64% of revenue, and functions as a smaller but useful contributor to diversification. Given its scale, swings here are less likely to drive the consolidated result compared to the infusion categories; however, consistent performance can still add incremental stability to the margin profile, especially if product cost management and pricing remain disciplined. Absent segment-level year-over-year disclosures, the key watch items are consistency in orders and the ability to maintain gross margin parity with the consolidated profile.

For the quarter at hand, Critical Care’s incremental contribution to EBIT growth is likely secondary to the dynamics within consumables and systems. Still, stable volumes and controlled costs can help preserve consolidated gross margin against possible variability in systems. To the extent that Critical Care volumes track in line with hospital utilization patterns and purchasing plans, this segment can continue to play a supportive role in earnings predictability. Any commentary indicating stable backlog and shipment cadence will help investors maintain confidence in baseline profitability.

What would validate or challenge consensus

Consensus embeds the idea that adjusted EPS can rise materially even if revenue is essentially flat year over year. Validation would come from sustained or improving gross margin near the recent 38.89% level, controlled operating expenses, and no material adverse developments tied to IV set evaluations. Positive EBIT progression toward the 83.83 million US dollars projection would similarly affirm the margin and cost thesis. An encouraging element would be reiterated confidence around second-half order timing and mix, reducing uncertainty around the systems line.

The main challenges to consensus would be a broader-than-anticipated scope of IV set actions, unexpected cost absorption, or a mix shift that pressures gross margin. If any of these materialize, the expected EPS uplift could compress despite stable top line. Conversely, clarification that the scope is narrow and remediations are behind the company could unlock sentiment upside, particularly if consumables demand holds and procurement costs remain well managed.

Analyst Opinions

Recent published views skew bullish, with four bullish opinions and no identifiable bearish calls in the period reviewed, producing a majority bullish ratio. Jefferies reaffirmed a Buy rating and set a 175 US dollars price target, signaling confidence in margin progression and earnings visibility into the second half. Piper Sandler maintained a Buy rating with a 163 US dollars target, emphasizing the durability of the core infusion franchise and scope for continued adjusted EPS expansion even if revenue trends remain subdued.

Needham upgraded the shares to Buy with a 165 US dollars price target, citing improved risk-reward as cost and margin execution become more visible and as operational performance stabilizes. BTIG initiated at Buy with a 170 US dollars price target, highlighting the earnings algorithm implied by consensus—steady revenue, improving margins, and higher adjusted EPS—as realistic under current operating conditions. These bullish stances collectively point to a view that margin quality and cost control can carry the quarter despite limited top-line growth.

The core of the bullish case centers on three elements. First, adjusted EPS leverage is expected to persist, with consensus modeling 27.57% year-over-year growth to 1.91 even as revenue edges down 1.67% year over year to 533.43 million US dollars; this implies operational improvements rather than reliance on one-time factors. Second, the portfolio’s sales mix, led by Infusion Consumables at 278.28 million US dollars last quarter, offers a foundation for gross margin resilience around the recent 38.89% level, supporting EBIT growth of 17.08% year over year implied by the 83.83 million US dollars forecast. Third, analysts anticipate that any IV set–related developments will be manageable in scope, with potential for clarity to reduce near-term uncertainty and limit impact to run-rate demand.

Within that framework, the majority view expects execution to be the key differentiator this quarter: sustaining consumables throughput, controlling product and logistics costs, and keeping operating expenses aligned with revenue. If those elements hold, the company should be positioned to meet or exceed consensus on adjusted EPS while holding revenue near projected levels. Analysts also point to the previous quarter’s outperformance on adjusted EPS relative to consensus as an indicator that margin management is tracking, with the coming print serving as a validation point for whether the cadence can continue through the balance of the year.